ICOS Antikörper (PE)

Produktnummer ABIN2663293

Dieser Hamster Monoklonal Antikörper erkennt spezifisch ICOS in ELISA (Detection). Er zeigt eine Reaktivität gegenüber Maus.

Kurzübersicht für ICOS Antikörper (PE) (ABIN2663293)

Target: ICOS (Inducible T-Cell Co-Stimulator (ICOS))

Reaktivität: Maus

Wirt: Hamster

Klonalität: Monoklonal

Konjugat: Dieser ICOS Antikörper ist konjugiert mit PE

Applikation: ELISA (Detection)

Klon: 15F9

Produktdetails anti-ICOS Antikörper (PE)

Aufreinigung: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu ICOS

Target: ICOS (Inducible T-Cell Co-Stimulator (ICOS))

Andere Bezeichnung: CD278

Hintergrund: CD278 is a 47-57 kD protein, also known as inducible costimulatory molecule (ICOS), or H4. This protein is homologous to the CD28/CTLA-4 proteins. It forms homodimers and is expressed on activated T cells and a subset of thymocytes. It is able to costimulate T cells proliferation. In addition, ICOS has been shown to be involved in humoral immune responses (B cell germinal center formation). The ICOS ligand is B7-H2. ICOS stimulation has been shown to potentiate TCR-mediated IL-4 and IL-10 production and has been proposed to play a role in Th2 cell development. It has also been shown to be involved in airway tolerance and the downregulation of pulmonary inflammation.

Pathways: Cancer Immune Checkpoints